Advances in Systemic Therapy and Radiotherapy for the Treatment of Lung Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 15 January 2025 | Viewed by 321
Special Issue Editor
Special Issue Information
Dear Colleagues,
Lung cancer remains a formidable global health challenge, but recent advancements in both radiation and systemic therapy have redefined its management landscape. This Special Issue serves as a testament to the relentless pursuit of improved treatment strategies. In the realm of radiation therapy, innovations in precision and targeted delivery have revolutionized our ability to obliterate tumor cells while sparing healthy tissue. Simultaneously, systemic therapies have witnessed groundbreaking developments, with the emergence of immunotherapies and targeted therapies as well as the refinement of traditional chemotherapy regimens. These strides reflect a paradigm shift in lung cancer care, offering patients more tailored and effective options, prolonging survival, and enhancing the quality of life. This Issue delves into the promising breakthroughs, current challenges, and future directions at the intersection of radiation and systemic therapies in lung cancer management.
Dr. Gaurav Marwaha
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- chemoradiation
- targeted therapy
- immunotherapy
- oligometastases
- SBRT
- biomarkers
- NSCLC
- small-cell lung cancer
- PCI
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
